The PARAMOUNT study

Efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in patients with heart failure and preserved ejection fraction

2012-08-27

(Press-News.org) Munich, Germany – The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial.

Approximately half of all heart failure patients have normal or nearly normal ejection fraction, a measure of their strength of cardiac contraction. However, while many studies have shown a benefit of pharmacological therapies in heart failure with reduced ejection fraction, so far, according to the latest ESC heart failure guidelines, no treatment has been shown to reduce mortality or morbidity in HFpEF.

The PARAMOUNT study, a phase II trial conducted in 308 patients in 13 countries, compared the effects of LCZ696, a new angiotensin receptor neprilysin inhibitor, and the ARB valsartan on the concentrations of natriuretic peptides. The natriuretic peptide investigated in this study, NT-proBNP, is a marker of cardiac wall stress, and levels are increased in patients with heart failure.

Study results presented here today showed that LCZ696 reduced levels of NT-proBNP by 23% when compared with valsartan. LCZ696 also reduced enlargement of the left atrium, another marker of adverse outcomes in heart failure, and improved the symptoms of heart failure.

According to the study's lead author Professor Scott Solomon, Professor of Medicine at Harvard Medical School and Director of Noninvasive Cardiology at Brigham and Women's Hospital, Boston, LCZ696 acts by inhibiting both the angiotensin receptor and the enzyme responsible for the breakdown of the natriuretic peptides (neprilysin). LCZ696's dual mechanism of action thus acts to restore the altered neurohormonal balance in HFpEF. Earlier research has suggested that the clinical benefits derived from neprilysin inhibition may be best achieved if the renin-angiotensin system is simultaneously inhibited.

"LCZ696 is unique in simultaneously blocking the renin angiotensin system while augmenting the body's intrinsic natriuretic peptide system through neprilysin inhibition," said Professor Solomon. "These dual effects may be important in the treatment of HFpEF.

"LCZ696 in the PARAMOUNT study is the first compound to show both reductions in NT-proBNP and left atrial size in HFpEF patients, each powerful predictors of outcome in heart failure. The favorable effects of LCZ696 seen in patients with HFpEF in PARAMOUNT are encouraging, and further testing of this agent in this patient population is warranted."

### Notes to editors

Heart failure is a growing clinical challenge associated with substantial morbidity and mortality. It affects about 2% of the western population and is the leading cause of hospital admission for people over 65 years of age. The PARAMOUNT study was sponsored by Novartis.

Please note that the author's photo and CV as well as the spokesperson's CV can be found here

About the European Society of Cardiology www.escardio.org The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2012 The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available at: http://spo.escardio.org/Welcome.aspx?eevtid=54 More information is available from the ESC Press Office at press@escardio.org. END

ELSE PRESS RELEASES FROM THIS DATE:

The Aldo-DHF study

2012-08-27

Munich, Germany – Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012. Behind his conclusion lay results showing that mineralocorticoid receptor blockade with spironolactone improves cardiac function and structure, reduces neuroendocrine activation, and effectively reduces blood pressure in a patient population with symptomatic predominantly ...

Obesity triggers AF in fertile women

2012-08-27

Munich, Germany – Obesity triggers atrial fibrillation in fertile women, according to research presented today at the ESC Congress 2012 by Dr Deniz Karasoy from Denmark. Atrial fibrillation and obesity are among the largest public health related challenges in the western world today. Atrial fibrillation is the commonest heart rhythm disorder and is associated with increased mortality and morbidity. Previous studies have demonstrated that obesity increases the risk of new-onset atrial fibrillation in individuals with known risk factors for developing atrial fibrillation ...

Female gender increases stroke risk in AF patients aged over 75 years by 20%

2012-08-27

Munich, Germany – Female gender increases the risk of stroke in patients with atrial fibrillation (AF) aged >75 years by 20%, according to a study presented today at the ESC Congress 2012. The findings were presented by Anders Mikkelsen, from Denmark. The results suggest that female gender should not be included as an independent stroke/thromboembolism (TE) risk factor in guidelines or risk stratification schemes used in treatment of patients with atrial fibrillation. The increased risk of stroke and TE in patients with atrial fibrillation depends on additional risk ...

Women with acute heart failure have similar in-hospital mortality to men but are less treated

2012-08-27

Munich, Germany – Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece. Acute heart failure (AHF) is a frequent clinical situation with high short- and long-term mortality as well as high hospitalization rates. The Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF) is an in-hospital chart audit survey which includes patients hospitalized ...

Drug eluting stents used less often in women than men

2012-08-27

Munich, Germany – Drug eluting stents (DES) are used less often in women treated with percutaneous coronary intervention (PCI) for coronary artery disease than men treated with PCI for the same condition, according to research presented today, August 25, at the ESC Congress 2012. The findings from a country-wide Germany registry were presented by Dr Martin Russ. Coronary artery disease is still a leading cause of mortality and morbidity in Europe and worldwide. During treatment with PCI, cardiologists can use bare metal stents (BMS) or the newer DES. While they do not ...

Passive smoking increases platelet activation in healthy people

2012-08-27

"It is well known that passive smoking is harmful for cardiovascular health, but the mechanism has not yet been discovered," said Dr Kaya. "We investigated the effects of passive smoking on the levels of three parameters – mean platelet volume (MPV), carboxyhemoglobin (COHb) and lactate - in an effort to further understand this mechanism. We also looked at the correlation between the three parameters." Mean platelet volume (MPV) is a well established indicator of platelet activation that is increased in acute thrombotic events. It is suspected that carbon monoxide (CO) ...

Continuous spinal cord stimulation improves heart function

2012-08-27

Munich, Germany – Spinal cord stimulation improves heart function and could become a novel treatment option for heart failure, according to research presented at the ESC Congress 2012 today, August 25, by Professor Hung-Fat Tse from Hong Kong. Heart failure is a progressive weakening of the heart muscle. It is a chronic condition that occurs when the heart cannot pump blood to meet the body's needs. When heart failure is present, not enough blood is circulating, which may cause fatigue. Further, fluid accumulation in the abdomen and legs and congestion in the lungs is ...

Copeptin predicts prognosis in HF patients

2012-08-27

Munich, Germany – Copeptin predicts prognosis in patients with heart failure, according to research presented at the ESC Congress today, August 25, by Professor Stefan Störk from Germany. Increased levels of copeptin were associated with increased frequencies of typical co-morbidities of heart failure, increased severity of heart failure, and increased risk of all-cause death. "Knowledge on the prognosis of patients with a chronic condition enables the physician to tailor the speed and intensity of treatment options to the individual patient," said Professor Störk. ...

Sudden death less likely in exercise related cardiac arrests

2012-08-27

Munich, Germany – People who have a cardiac arrest during or shortly after exercise are three times more likely to survive than those who have a cardiac arrest that is not exercise related, according to research presented at the ESC Congress 2012 today, August 26. The findings from the Amsterdam Resuscitation Study (ARREST) were presented by Dr Arend Mosterd from the Netherlands. "Although physical activity is the best way to promote cardiovascular health, exercise can also trigger an acute cardiac event leading to death," said Dr Mosterd. "These dramatic and often high ...

Novel blood test predicts sudden death risk patients who would benefit from ICDs

2012-08-27

Munich, Germany – A novel blood test that predicts sudden death risk in heart failure patients is set to help physicians decide which patients would benefit from implantable cardioverter defibrillators (ICDs). The findings were presented at the ESC Congress 2012 today, August 26, by Professor Samuel Dudley from Chicago, IL, US. Approximately 5 million patients in the US have heart failure, a condition where the heart is unable to pump blood adequately, and nearly 550,000 people are diagnosed annually. Heart failure is the single most common cause of admission to hospitals ...

Groundbreaking cancer therapy clinical trial with US Department of Energy’s accelerator-produced actinium-225 set to begin this summer

Tens of thousands of heart attacks and strokes could be avoided each year if cholesterol-lowering drugs were used according to guidelines

Leading cancer and metabolic disease expert Michael Karin joins Sanford Burnham Prebys

Low-intensity brain stimulation may restore neuron health in Alzheimer's disease

[Press-News.org] The PARAMOUNT study
Efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in patients with heart failure and preserved ejection fraction

The PARAMOUNT study

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: